Tyme Technologies (TYMI) 3.6000 $TYMI Tyme Tech
Post# of 273254
Posted On: 09/20/2016 7:17:59 AM
Tyme Technologies (TYMI) 3.6000 $TYMI
Tyme Technologies Begins Phase 1b/2 Clinical Trial for the Treatment of Prostate Cancer
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Tyme Technologies, Inc. (OTCQB:TYMI) ("Tyme"
, a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that it has begun recruiting for a Phase 1b/2 clinical trial, using its proprietary compound, SM-88, to treat prostate cancer. Unlike traditional chemotherapy, SM-88 is designed to target only active cancer cells.
Tyme Technologies' Chief Medical Officer, Dr. Giuseppe Del Priore, Presents at 2016 ACOG Annual Clinical and Scientific Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that its Chief Medical Officer (CMO), Dr. Giuseppe Del Priore joined an elite group of national and international experts to discuss cancer-related topics at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington, DC. As part of the "Lunch with the Experts" program, Dr. Del Priore led two dynamic small group discussions: Medical Treatment of HPV-Related Diseases and Medical Management of Dysplasia.
New York Times Article Spotlights Potential Role of Metabolism-Centered Therapies in Fighting Cancer
GlobeNewswire - Wed Jun 01, 7:00AM CDT
According to Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, conclusions cited in the May 15, 2016, New York Times Magazine article, "An Old Idea, Revived: Starve Cancer to Death," support the science behind its proprietary compound, SM-88.
Tyme Technologies Announces First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 7:30AM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications has reported financial results for the quarter ended March 31, 2016.
Tyme Technologies, Inc. Reports Year-End Financial Results for 2015
BusinessWire - Mon Apr 11, 7:30AM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly-targeted cancer therapeutics for a broad range of oncology indications has reported financial results for the year ended December 31, 2015.
Tyme Technologies, Inc. Reports Third Quarter 2015 Financial Results
BusinessWire - Mon Nov 23, 7:30AM CST
Tyme Technologies, Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer in humans and operating through its wholly-owned subsidiary Tyme Inc., today reported financial results for the quarter ended September 30, 2015. The Company also provided updated financial guidance for 2015.
Tyme Technologies, Inc. Receives FDA Acceptance of Investigational New Drug Application for Oncology Drug Candidate, SM-88
BusinessWire - Mon Oct 26, 3:30PM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a research and development company operating through its wholly-owned subsidiary, Tyme Inc., focused on development and eventual commercialization of oncology products, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) Application for SM-88, its breast cancer drug candidate.
Tyme Technologies, Inc. Submits Investigational New Drug Application for Oncology Drug Candidate SM-88
BusinessWire - Wed Sep 30, 7:30AM CDT
Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a research and development company focused on developing first-in-class oncology drug candidates, has submitted a Phase 2 Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for SM-88, a drug candidate with a unique metabolic approach that has demonstrated initial efficacy and low toxicity in the treatment of multiple types of cancers.
Tyme Technologies, Inc. Appoints Mario Eisenberger, MD to its Medical Advisory Board
BusinessWire - Mon Sep 14, 7:30AM CDT
Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a cancer research company focused on developing and commercializing products in the oncology space, announced the appointment of Mario Eisenberger, MD to its Medical Advisory Board. Dr. Eisenberger is renowned with more than 30 years of oncology experience and, as a member the Tyme, Inc. Medical Advisory Board, will offer oversight in clinical and medical affairs. Dr. Eisenberger, in addition to being an accomplished doctor, is a scientist, educator and highly-prized guest speaker. He is currently Professor of urology and oncology at Johns Hopkins University School of Medicine, with a practice specializing in the treatment of cancers of the bladder, kidney, prostate and testicles.
Tyme Technologies, Inc. Reports Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 14, 7:30AM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer, today reported financial results for the quarter ended June 30, 2015.
Tyme Technologies, Inc. Completes Reverse Merger
BusinessWire - Thu Mar 19, 7:30AM CDT
--Wholly-Owned Subsidiary Tyme Inc. to Focus on Developing Oncology Drug Candidates
Tyme Technologies Begins Phase 1b/2 Clinical Trial for the Treatment of Prostate Cancer
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Tyme Technologies, Inc. (OTCQB:TYMI) ("Tyme"
, a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that it has begun recruiting for a Phase 1b/2 clinical trial, using its proprietary compound, SM-88, to treat prostate cancer. Unlike traditional chemotherapy, SM-88 is designed to target only active cancer cells. Tyme Technologies' Chief Medical Officer, Dr. Giuseppe Del Priore, Presents at 2016 ACOG Annual Clinical and Scientific Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that its Chief Medical Officer (CMO), Dr. Giuseppe Del Priore joined an elite group of national and international experts to discuss cancer-related topics at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington, DC. As part of the "Lunch with the Experts" program, Dr. Del Priore led two dynamic small group discussions: Medical Treatment of HPV-Related Diseases and Medical Management of Dysplasia.
New York Times Article Spotlights Potential Role of Metabolism-Centered Therapies in Fighting Cancer
GlobeNewswire - Wed Jun 01, 7:00AM CDT
According to Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, conclusions cited in the May 15, 2016, New York Times Magazine article, "An Old Idea, Revived: Starve Cancer to Death," support the science behind its proprietary compound, SM-88.
Tyme Technologies Announces First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 7:30AM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications has reported financial results for the quarter ended March 31, 2016.
Tyme Technologies, Inc. Reports Year-End Financial Results for 2015
BusinessWire - Mon Apr 11, 7:30AM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly-targeted cancer therapeutics for a broad range of oncology indications has reported financial results for the year ended December 31, 2015.
Tyme Technologies, Inc. Reports Third Quarter 2015 Financial Results
BusinessWire - Mon Nov 23, 7:30AM CST
Tyme Technologies, Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer in humans and operating through its wholly-owned subsidiary Tyme Inc., today reported financial results for the quarter ended September 30, 2015. The Company also provided updated financial guidance for 2015.
Tyme Technologies, Inc. Receives FDA Acceptance of Investigational New Drug Application for Oncology Drug Candidate, SM-88
BusinessWire - Mon Oct 26, 3:30PM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a research and development company operating through its wholly-owned subsidiary, Tyme Inc., focused on development and eventual commercialization of oncology products, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) Application for SM-88, its breast cancer drug candidate.
Tyme Technologies, Inc. Submits Investigational New Drug Application for Oncology Drug Candidate SM-88
BusinessWire - Wed Sep 30, 7:30AM CDT
Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a research and development company focused on developing first-in-class oncology drug candidates, has submitted a Phase 2 Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for SM-88, a drug candidate with a unique metabolic approach that has demonstrated initial efficacy and low toxicity in the treatment of multiple types of cancers.
Tyme Technologies, Inc. Appoints Mario Eisenberger, MD to its Medical Advisory Board
BusinessWire - Mon Sep 14, 7:30AM CDT
Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a cancer research company focused on developing and commercializing products in the oncology space, announced the appointment of Mario Eisenberger, MD to its Medical Advisory Board. Dr. Eisenberger is renowned with more than 30 years of oncology experience and, as a member the Tyme, Inc. Medical Advisory Board, will offer oversight in clinical and medical affairs. Dr. Eisenberger, in addition to being an accomplished doctor, is a scientist, educator and highly-prized guest speaker. He is currently Professor of urology and oncology at Johns Hopkins University School of Medicine, with a practice specializing in the treatment of cancers of the bladder, kidney, prostate and testicles.
Tyme Technologies, Inc. Reports Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 14, 7:30AM CDT
Tyme Technologies, Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer, today reported financial results for the quarter ended June 30, 2015.
Tyme Technologies, Inc. Completes Reverse Merger
BusinessWire - Thu Mar 19, 7:30AM CDT
--Wholly-Owned Subsidiary Tyme Inc. to Focus on Developing Oncology Drug Candidates
(0)
(0)Scroll down for more posts ▼